Evantuzumab belongs to a new type of drug, which has not yet been listed in China, so there is no pricing in China at present, and its foreign reference price is about 35,000 yuan a bottle. Evantuzumab can bind to the surface of tumor cells, promote the destruction of tumor cells by the body’s immune cells, clinically mainly used for the treatment of locally advanced or metastatic non-small cell lung cancer adult patients with epidermal growth factor receptor exon 20 insertion mutation. However, the drug has not been approved for marketing in China, so it is not possible to know its specific price, if abroad, the reference price is around 35,000 yuan. The most common adverse reactions to this product are onychomycosis, rash, dyspnea, musculoskeletal pain, nausea, edema, fatigue, stomatitis, cough, constipation and vomiting, and its contraindications are not clear. Please purchase and use this product under the guidance of a physician, and consult your physician promptly if you experience significant discomfort after use.